CP and autosomal dominant polycystic kidney disease: In summary, our studies show the therapeutic potential and safety of KM-drugs loaded into CP as a strategy for combined kidney-targeting and oral drug delivery in ADPKD, and this transformative work extends far beyond ADPKD, offering invaluable insights applicable to a broad range of chronic and genetic kidney diseases which can greatly benefit from targeted drug delivery strategies but currently have no nanomedicine options in the clinic.